Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific announces new CEO for portfolio company Wanda

Wanda uses machine learning in place of conventional technologies, thus enabling clinicians to make more informed care decisions
Doctor and patient
Wanda's technology has been shown to predict 90% of hospital readmissions up to seven days in advance.

NetScientific PLC (LON:NSCI), the backer of fledgling healthcare companies, said digital health company Wanda has a new chief executive officer.

Foad Dabiri, who has been Wanda’s chief technology officer since March 2014, will be taking over from Steve Curd as chief executive officer (CEO) with immediate effect.

Curd had been Wanda’s CEO since September 2015.

Dabiri will take the company through its commercialisation stage, said NetScientific.

"Foad's unique understanding of the nexus between predictive analytics, data and patient need, make him the best person to lead Wanda at this critical juncture as it moves into its commercialisation phase,” said François Martelet, who is CEO of NetScientific and chairman of Wanda.

San Francisco-based Wanda is one of NetScientific’s portfolio companies.

It is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions.

John-H.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
dimerix-CEO-Kathy-Harrisson-757.png
Thu
Dimerix Limited has recently received an R&D tax refund.
a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use